Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
NASDAQ
Unprofitable
Unprofitable
2B
Biotechnology
Next Earning date - 07 Nov 2024
2B
Biotechnology
Next Earning date - 07 Nov 2024
Relative Strenght
89Volume Buzz
-38%Earning Acce
NoDist 52w H.
22%